CRISPR/Cas9-Mediated Genome Editing for Huntington’s Disease
Authors:
- 1 June 2018
- book chapter
- Published by Springer Nature
- Vol. 1780, 463-481
Abstract
This chapter describes the potential use of viral-mediated gene transfer in the central nervous system for genome editing in the context of Huntington’s disease. Here, we provide protocols that cover the design of various genome editing strategies, the cloning of CRISPR/Cas9 elements into lentiviral vectors, and the assessment of cleavage efficiency, as well as potential unwanted effects.Keywords
This publication has 70 references indexed in Scilit:
- RNA-Guided Human Genome Engineering via Cas9Science, 2013
- Multiplex Genome Engineering Using CRISPR/Cas SystemsScience, 2013
- Common SNP-Based Haplotype Analysis of the 4p16.3 Huntington Disease Gene RegionThe American Journal of Human Genetics, 2012
- Optimizing Promoters for Recombinant Adeno-Associated Virus-Mediated Gene Expression in the Peripheral and Central Nervous System Using Self-Complementary VectorsHuman Gene Therapy, 2011
- HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East AsiaEuropean Journal of Human Genetics, 2011
- Genome editing with engineered zinc finger nucleasesNature Reviews Genetics, 2010
- Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease MiceMolecular Therapy, 2009
- Sustained effects of nonallele‐specific Huntingtin silencingAnnals of Neurology, 2009
- CAG Expansion in the Huntington Disease Gene Is Associated with a Specific and Targetable Predisposing HaplogroupThe American Journal of Human Genetics, 2009
- Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD MiceThe Journal of Neuroscience, 2008